Sage Therapeutics, Inc.
SAGE
$6.75
$0.192.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 74.98% | -83.56% | 337.08% | 249.80% | 139.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 77.97% | -83.56% | 337.08% | 249.80% | 139.89% |
| Cost of Revenue | -67.93% | -35.43% | -43.33% | -34.30% | -21.55% |
| Gross Profit | 85.64% | -477.26% | 54.42% | 41.71% | 27.47% |
| SG&A Expenses | 9.54% | -0.84% | -31.89% | -25.91% | -19.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -35.49% | -22.54% | -37.52% | -30.63% | -20.90% |
| Operating Income | 43.11% | -89.99% | 43.22% | 34.70% | 24.31% |
| Income Before Tax | 42.65% | -192.85% | 53.60% | 35.85% | 26.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 42.65% | -192.85% | 53.60% | 35.85% | 26.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.65% | -192.85% | 53.60% | 35.85% | 26.12% |
| EBIT | 43.11% | -89.99% | 43.22% | 34.70% | 24.31% |
| EBITDA | 43.05% | -91.53% | 43.26% | 34.76% | 24.37% |
| EPS Basic | 44.25% | -186.76% | 54.52% | 36.66% | 26.68% |
| Normalized Basic EPS | 44.71% | -119.88% | 45.42% | 36.66% | 26.68% |
| EPS Diluted | 44.25% | -186.76% | 54.52% | 36.66% | 26.68% |
| Normalized Diluted EPS | 44.71% | -119.88% | 45.42% | 36.66% | 26.68% |
| Average Basic Shares Outstanding | 2.86% | 2.12% | 2.01% | 1.29% | 0.77% |
| Average Diluted Shares Outstanding | 2.86% | 2.12% | 2.01% | 1.29% | 0.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |